…
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Washington, District Of Columbia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -7.37M | -7.96M | -3.81M | -6.18M | -4.26M |
| Minority interest | 0.00M | 0.01M | 0.01M | -0.00M | 0.01M |
| Net income | -7.37M | -7.95M | -3.77M | -6.18M | -4.25M |
| Selling general administrative | 6.28M | 5.02M | 4.24M | 1.30M | 1.12M |
| Gross profit | 0.22M | 0.22M | -0.22M | -0.21M | 0.31M |
| Reconciled depreciation | 0.08M | 0.06M | 0.10M | 0.08M | 0.07M |
| Ebit | -7.36M | -7.95M | -1.53M | -1.79M | -1.09M |
| Ebitda | -7.28M | -7.88M | -1.43M | -1.71M | -1.01M |
| Depreciation and amortization | 0.08M | 0.06M | 0.10M | 0.08M | 0.07M |
| Operating income | -7.76M | -9.71M | -5.15M | -1.75M | -1.12M |
| Other operating expenses | 8.76M | 10.32M | 5.41M | 1.97M | 2.28M |
| Interest expense | 0.01M | 0.01M | 2.29M | 3.99M | 3.17M |
| Tax provision | 0.00M | 0.00M | -0.00M | 0.00M | 0.00M |
| Net interest income | -0.01M | -0.01M | -3.39M | -3.99M | -3.17M |
| Income tax expense | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Total revenue | 1.01M | 0.61M | 0.25M | 0.22M | 1.16M |
| Total operating expenses | 7.98M | 9.94M | 4.93M | 1.54M | 1.43M |
| Cost of revenue | 0.78M | 0.38M | 0.47M | 0.43M | 0.85M |
| Total other income expense net | 0.39M | 1.76M | 1.34M | -0.44M | 0.04M |
| Net income from continuing ops | -7.37M | -7.96M | -3.44M | -6.18M | -4.26M |
| Net income applicable to common shares | - | - | - | -6.18M | -6.18M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 5.37M | 5.76M | 7.78M | 1.30M | 1.39M |
| Intangible assets | 0.22M | 0.16M | 0.23M | 0.16M | 0.11M |
| Other current assets | 0.98M | 1.07M | 4.40M | 0.20M | 0.22M |
| Total liab | 1.99M | 1.80M | 2.99M | 25.45M | 19.55M |
| Total stockholder equity | 3.46M | 4.04M | 4.87M | -23.58M | -17.58M |
| Other current liab | 0.37M | 0.64M | 2.31M | 1.69M | 0.00M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M | 4.98M |
| Capital stock | 9.57M | 9.57M | 9.86M | 0.00M | 4.98M |
| Retained earnings | -47.89M | -40.53M | -32.58M | -28.82M | -22.63M |
| Other liab | - | - | - | 0.26M | - |
| Cash | 1.51M | 1.66M | 2.14M | 0.26M | 0.12M |
| Total current liabilities | 1.84M | 1.66M | 2.84M | 23.92M | 0.64M |
| Current deferred revenue | - | - | - | 0.33M | -0.00M |
| Net debt | -1.36M | -1.50M | -1.97M | 22.15M | 18.69M |
| Short term debt | 0.01M | 0.01M | 0.02M | 21.15M | 0.05M |
| Short long term debt | 0.01M | 0.01M | 0.01M | 21.14M | - |
| Short long term debt total | 0.15M | 0.16M | 0.17M | 22.42M | 18.80M |
| Other stockholder equity | 41.65M | 34.86M | 27.46M | 5.16M | - |
| Property plant equipment | - | - | - | - | 0.11M |
| Total current assets | 4.90M | 5.39M | 7.24M | 1.10M | 1.18M |
| Net tangible assets | - | - | - | -23.74M | -17.69M |
| Short term investments | 1.24M | 1.73M | - | - | - |
| Net receivables | 0.51M | 0.49M | 0.23M | 0.05M | 0.15M |
| Long term debt | 0.14M | 0.15M | 0.15M | 1.27M | 18.74M |
| Inventory | 0.66M | 0.44M | 0.47M | 0.52M | 0.69M |
| Accounts payable | 1.46M | 1.01M | 0.51M | 0.76M | 0.59M |
| Accumulated other comprehensive income | 0.14M | 0.14M | 0.14M | 0.07M | 0.08M |
| Non currrent assets other | - | 0.07M | 0.24M | - | - |
| Non current assets total | 0.47M | 0.37M | 0.54M | 0.20M | 0.22M |
| Capital lease obligations | - | 0.00M | 0.01M | 0.01M | 0.06M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 0.47M | -1.89M | -0.11M | -0.06M | -0.04M |
| Change to liabilities | - | - | - | 0.00M | -0.84M |
| Total cashflows from investing activities | 0.25M | -1.89M | -0.12M | -0.06M | -0.06M |
| Net borrowings | - | 0.00M | -0.96M | - | 0.61M |
| Total cash from financing activities | 6.44M | 7.05M | 6.47M | 1.22M | 0.61M |
| Net income | -7.37M | -7.96M | -3.77M | -6.18M | -4.26M |
| Change in cash | -0.15M | -0.48M | 1.88M | 0.15M | -0.08M |
| Begin period cash flow | 1.66M | 2.14M | 0.26M | 0.12M | 0.19M |
| End period cash flow | 1.51M | 1.66M | 2.14M | 0.26M | 0.12M |
| Total cash from operating activities | -6.85M | -5.65M | -4.54M | -1.01M | -0.65M |
| Issuance of capital stock | 6.45M | 7.04M | 6.45M | - | - |
| Depreciation | 0.08M | 0.06M | 0.10M | 0.08M | 0.07M |
| Other cashflows from investing activities | 0.25M | -0.08M | -0.06M | - | - |
| Change to inventory | -0.47M | 0.02M | 0.21M | -0.05M | 0.31M |
| Change to account receivables | -0.02M | -0.26M | -0.19M | 0.10M | 0.71M |
| Other cashflows from financing activities | -0.02M | 0.01M | 0.98M | 1.22M | 0.68M |
| Change to netincome | - | - | - | 0.62M | 0.62M |
| Capital expenditures | 0.22M | 0.18M | 0.12M | 0.06M | 0.04M |
| Change in working capital | -0.01M | 0.19M | 0.41M | 3.31M | 2.90M |
| Stock based compensation | 0.46M | 3.61M | 1.52M | - | - |
| Other non cash items | -0.01M | -1.56M | -1.28M | 1.78M | 0.64M |
| Free cash flow | -7.07M | -5.83M | -4.66M | -1.07M | -0.68M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SXTP 60 Degrees Pharmaceuticals, Inc. Common Stock |
-0.03 6.36% |
0.47 | - | - | 2.45 | - | 10.74 | 22.23 |
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Washington, District Of Columbia.
1025 Connecticut Avenue NW, Washington, DC, United States, 20036
202 327 5422
3
| Name | Title | Year Born |
|---|---|---|
| Dr. Geoffrey Stuart Dow | Chairman, CEO & President | 1974 |
| Mr. Tyrone Miller | CFO & Treasurer | 1975 |
| Dr. Bryan Smith | Chief Medical Officer | 1966 |
| Ms. Kristen Landon | Chief Commercial Officer | 1967 |
| Ms. Jennifer Herz | Director | NA |
| Dr. Geoffrey Stuart Dow Ph.D. | Chairman, CEO & President | 1974 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.